JP2016512960A5 - - Google Patents

Download PDF

Info

Publication number
JP2016512960A5
JP2016512960A5 JP2015560341A JP2015560341A JP2016512960A5 JP 2016512960 A5 JP2016512960 A5 JP 2016512960A5 JP 2015560341 A JP2015560341 A JP 2015560341A JP 2015560341 A JP2015560341 A JP 2015560341A JP 2016512960 A5 JP2016512960 A5 JP 2016512960A5
Authority
JP
Japan
Prior art keywords
nucleic acid
cells
talen
gene
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015560341A
Other languages
English (en)
Japanese (ja)
Other versions
JP6480874B2 (ja
JP2016512960A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/019322 external-priority patent/WO2014134412A1/en
Publication of JP2016512960A publication Critical patent/JP2016512960A/ja
Publication of JP2016512960A5 publication Critical patent/JP2016512960A5/ja
Priority to JP2019021260A priority Critical patent/JP6893945B2/ja
Application granted granted Critical
Publication of JP6480874B2 publication Critical patent/JP6480874B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015560341A 2013-03-01 2014-02-28 Talenに基づく遺伝子修正 Expired - Fee Related JP6480874B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019021260A JP6893945B2 (ja) 2013-03-01 2019-02-08 Talenに基づく遺伝子修正

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361771735P 2013-03-01 2013-03-01
US61/771,735 2013-03-01
PCT/US2014/019322 WO2014134412A1 (en) 2013-03-01 2014-02-28 Talen-based gene correction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019021260A Division JP6893945B2 (ja) 2013-03-01 2019-02-08 Talenに基づく遺伝子修正

Publications (3)

Publication Number Publication Date
JP2016512960A JP2016512960A (ja) 2016-05-12
JP2016512960A5 true JP2016512960A5 (cg-RX-API-DMAC7.html) 2017-03-30
JP6480874B2 JP6480874B2 (ja) 2019-03-13

Family

ID=51428832

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015560341A Expired - Fee Related JP6480874B2 (ja) 2013-03-01 2014-02-28 Talenに基づく遺伝子修正
JP2019021260A Expired - Fee Related JP6893945B2 (ja) 2013-03-01 2019-02-08 Talenに基づく遺伝子修正
JP2021015441A Pending JP2021088565A (ja) 2013-03-01 2021-02-03 Talenに基づく遺伝子修正

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019021260A Expired - Fee Related JP6893945B2 (ja) 2013-03-01 2019-02-08 Talenに基づく遺伝子修正
JP2021015441A Pending JP2021088565A (ja) 2013-03-01 2021-02-03 Talenに基づく遺伝子修正

Country Status (7)

Country Link
US (4) US9393257B2 (cg-RX-API-DMAC7.html)
EP (2) EP2961262B1 (cg-RX-API-DMAC7.html)
JP (3) JP6480874B2 (cg-RX-API-DMAC7.html)
AU (2) AU2014223243B2 (cg-RX-API-DMAC7.html)
CA (1) CA2902954A1 (cg-RX-API-DMAC7.html)
ES (1) ES2750550T3 (cg-RX-API-DMAC7.html)
WO (1) WO2014134412A1 (cg-RX-API-DMAC7.html)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9850497B2 (en) * 2013-11-04 2017-12-26 Regents Of The University Of Minnesota Gene targeting methods and tools
MX372651B (es) * 2014-01-31 2020-06-16 Factor Bioscience Inc ARN SINTÉTICO PARA SU Uso EN EL TRATAMIENTO DE LA EPIDERMÓLISIS AMPOLLOSA DISTRÓFICA.
MX2017006408A (es) 2014-11-17 2018-03-23 Adicet Bio Inc Linfocitos t gamma delta modificados geneticamente.
JP7199809B2 (ja) 2015-02-13 2023-01-06 ファクター バイオサイエンス インコーポレイテッド 核酸製品及びその投与方法
CN104726495B (zh) * 2015-03-25 2018-06-19 西北农林科技大学 一种基于talen介导的基因打靶敲除山羊blg的载体及重组细胞
JP2018513681A (ja) 2015-03-31 2018-05-31 エクセリゲン サイエンティフィック, インコーポレイテッドExeligen Scientific, Inc. 細胞または生物のゲノムへのDNA配列の標的化組み込みのためのCas9レトロウイルスインテグラーゼおよびCas9レコンビナーゼ系
EP3292219B9 (en) 2015-05-04 2022-05-18 Ramot at Tel-Aviv University Ltd. Methods and kits for fragmenting dna
CN114634943A (zh) 2015-05-18 2022-06-17 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
GB2592821B (en) 2015-07-31 2022-01-12 Univ Minnesota Modified cells and methods of therapy
US20180296600A1 (en) * 2015-10-27 2018-10-18 The Board Of Trustees Of The Leland Stanford Junior University Treatment of epidermolysis bullosa by injection of autologous collagen vii overexpressing leukocytes
WO2017176336A1 (en) * 2016-04-08 2017-10-12 Krystal Biotech, LLC Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
WO2017197347A1 (en) 2016-05-12 2017-11-16 Adicet Bio, Inc. METHODS FOR SELECTIVE EXPANSION OF γδ T-CELL POPULATIONS AND COMPOSITIONS THEREOF
EP3494138A1 (en) 2016-08-02 2019-06-12 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
EP3500585A4 (en) 2016-08-17 2020-04-01 Factor Bioscience Inc. NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION
GB2564823B8 (en) 2016-10-07 2022-06-29 Tcr2 Therapeutics Inc Compositions and methods for TCR reprogramming using fusion proteins
CA3041068A1 (en) 2016-10-18 2018-04-26 Regents Of The University Of Minnesota Tumor infiltrating lymphocytes and methods of therapy
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2018119298A1 (en) 2016-12-21 2018-06-28 TCR2 Therapeutics Inc. Engineered t cells for the treatment of cancer
US12344826B2 (en) 2017-01-25 2025-07-01 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation Apparatus and methods for in vitro preclinical human trials
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
EP3585897A1 (en) * 2017-02-22 2020-01-01 CRISPR Therapeutics AG Materials and methods for treatment of dystrophic epidermolysis bullosa (deb) and other collagen type vii alpha 1 chain (col7a1) gene related conditions or disorders
WO2018229226A1 (en) 2017-06-14 2018-12-20 Technische Universität Dresden Methods and means for genetic alteration of genomes utilizing designer dna recombining enzymes
KR20200016298A (ko) 2017-06-19 2020-02-14 국립대학법인 홋가이도 다이가쿠 표피 수포증 치료제
CN111511375A (zh) 2017-06-30 2020-08-07 因提玛生物科学公司 用于基因治疗的腺相关病毒载体
JP2021502816A (ja) 2017-11-15 2021-02-04 アディセット バイオ, インコーポレイテッド δ3γδT細胞集団の選択的増殖方法及びその組成物
US10525090B2 (en) 2018-04-12 2020-01-07 Krystal Biotech, Inc. Compositions and methods for the treatment of autosomal recessive congenital ichthyosis
WO2019204226A1 (en) 2018-04-16 2019-10-24 University Of Massachusetts Compositions and methods for improved gene editing
CN119523872A (zh) 2018-04-27 2025-02-28 克里斯托生物技术股份有限公司 用于美容性应用的编码一种或多种美容蛋白的重组核酸
EP4656196A2 (en) 2018-05-11 2025-12-03 Memorial Sloan-Kettering Cancer Center T cell receptors targeting pik3ca mutations and uses thereof
CN112384063A (zh) 2018-06-07 2021-02-19 以色列国家农业部、农村发展农业研究组织·沃尔卡尼中心 再生及转殖大麻的方法
WO2019234754A1 (en) 2018-06-07 2019-12-12 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Nucleic acid constructs and methods of using same
EP3847243A1 (en) * 2018-09-07 2021-07-14 Wisconsin Alumni Research Foundation Generation of hematopoietic progenitor cells from human pluripotent stem cells
JP7562515B2 (ja) 2018-09-24 2024-10-07 クリスタル バイオテック インコーポレイテッド ネザートン症候群の治療のための組成物及び方法
WO2020112860A1 (en) 2018-11-30 2020-06-04 Intima Bioscience, Inc. Methods of identifying immunomodulatory genes
JP2022510387A (ja) 2018-12-03 2022-01-26 アディセット バイオ, インコーポレイテッド ガンマデルタt細胞集団の選択的生体内増殖方法及びその組成物
WO2020163703A1 (en) 2019-02-08 2020-08-13 Krystal Biotech, Inc. Compositions and methods for delivering cftr polypeptides
KR20220004060A (ko) 2019-04-05 2022-01-11 루트패스 제노믹스, 인크. T-세포 수용체 유전자 어셈블리를 위한 조성물 및 방법
CA3143327A1 (en) 2019-06-13 2020-12-17 J. Keith Joung Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
WO2020257553A1 (en) 2019-06-20 2020-12-24 Memorial Sloan-Kettering Cancer Center T cell receptors targeting pik3ca mutations and uses thereof
WO2020257684A1 (en) 2019-06-20 2020-12-24 University Of Massachusetts Compositions and methods for improved gene editing
CN114450265B (zh) 2019-07-03 2024-12-24 菲克特生物科学股份有限公司 阳离子脂质及其用途
WO2021011936A2 (en) 2019-07-18 2021-01-21 University Of Rochester Cell-type selective immunoprotection of cells
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
MX2022002613A (es) 2019-09-03 2022-06-02 Myeloid Therapeutics Inc Metodos y composiciones para la integracion del genoma.
US12091681B2 (en) 2020-03-27 2024-09-17 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
WO2022003568A1 (en) 2020-06-30 2022-01-06 Dcprime B.V. Use of leukemia-derived cells in ovarian cancer vaccines
CN116670154A (zh) 2020-07-24 2023-08-29 总医院公司 增强的病毒样颗粒及使用其递送至细胞的方法
IL301021A (en) 2020-09-01 2023-05-01 64 X Inc Mammalian cells and methods for engineering the same
JP2023546950A (ja) 2020-10-23 2023-11-08 ルートパス・ジェノミクス,インコーポレーテッド T細胞受容体同定のための組成物及び方法
WO2022155500A1 (en) 2021-01-14 2022-07-21 Senti Biosciences, Inc. Secretable payload regulation
WO2022157715A1 (en) 2021-01-22 2022-07-28 Dcprime B.V. Methods of tumor vaccination
EP4304633A1 (en) 2021-03-12 2024-01-17 Mendus B.V. Methods of vaccination and use of cd47 blockade
US11779660B2 (en) 2021-04-02 2023-10-10 Krystal Biotech, Inc. Viral vectors for cancer therapy
GB2623653A (en) 2021-05-11 2024-04-24 Myeloid Therapeutics Inc Methods and compositions for genomic integration
WO2023086847A1 (en) 2021-11-10 2023-05-19 Encodia, Inc. Methods for barcoding macromolecules in individual cells
EP4493681A1 (en) 2022-03-17 2025-01-22 Keshihua (Nanjing) Biotechnology Co., Ltd Synthetic tumor-infiltrating lymphocytes (tils)
WO2024039576A2 (en) 2022-08-19 2024-02-22 Memorial Sloan-Kettering Cancer Center T cell receptors targeting ras mutations and uses thereof
KR20250126156A (ko) 2022-11-18 2025-08-22 교토후고리츠다이가쿠호진 미토파지 유도를 위한 조성물 및 그의 용도
WO2025128981A1 (en) 2023-12-14 2025-06-19 Sohm, Inc. Compositions and methods for genome editing

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002099070A2 (en) * 2001-06-04 2002-12-12 Corixa Corporation Compositions and methods for high-level, large-scale production of recombinant proteins
WO2011072246A2 (en) * 2009-12-10 2011-06-16 Regents Of The University Of Minnesota Tal effector-mediated dna modification
WO2012033462A1 (en) 2010-09-06 2012-03-15 Temasek Life Sciences Laboratory Limited Molecular interaction between xa10 and avrxa10
DK2638163T3 (en) * 2010-11-12 2017-07-24 Massachusetts Gen Hospital POLYCOMB-ASSOCIATED NON-CODING RNAs
IL293650B2 (en) 2011-09-21 2024-10-01 Sangamo Therapeutics Inc Methods and compositions for regulation of transgene expression

Similar Documents

Publication Publication Date Title
JP2016512960A5 (cg-RX-API-DMAC7.html)
McCutcheon et al. Epigenome editing technologies for discovery and medicine
Ran et al. Genome engineering using the CRISPR-Cas9 system
CN107208078B (zh) 使用成对向导rna进行靶向遗传修饰的方法和组合物
Gratz et al. CRISPR‐Cas9 genome editing in Drosophila
Puchta Using CRISPR/Cas in three dimensions: towards synthetic plant genomes, transcriptomes and epigenomes
US10106820B2 (en) Methods and compositions for modifying a targeted locus
US10858662B2 (en) Genome editing with split Cas9 expressed from two vectors
JP2017070287A5 (cg-RX-API-DMAC7.html)
JP2016500262A5 (cg-RX-API-DMAC7.html)
JP2016027807A5 (cg-RX-API-DMAC7.html)
EP4306642A3 (en) Compositions and methods for modifying genomes
EP4317443A3 (en) Compositions and methods for modifying genomes
JP2018530336A5 (cg-RX-API-DMAC7.html)
JP2016521993A5 (cg-RX-API-DMAC7.html)
FI3690056T3 (fi) Menetelmiä ja tuotteita nukleiinihapon valmistamiseksi ja viemiseksi
EP4310196A3 (en) Methods and compositions for manipulating nucleic acids
JP2020519304A5 (cg-RX-API-DMAC7.html)
FI3445388T3 (fi) Materiaaleja ja menetelmiä hemoglobinopatioiden hoitamiseksi
Gibson et al. What rheumatologists need to know about CRISPR/Cas9
JP2020511931A5 (cg-RX-API-DMAC7.html)
Murata Minichromosomes and artificial chromosomes in Arabidopsis
Guo et al. Target site recognition by a diversity-generating retroelement
CN104388456A (zh) 一种同时表达两条sgRNA的载体的构建方法
Lakhotia Central dogma, selfish DNA and noncoding Rnas: A historical perspective